Literature DB >> 1673712

Brain growth and cognitive improvement in children with human immunodeficiency virus-induced encephalopathy after 6 months of continuous infusion zidovudine therapy.

C DeCarli1, L Fugate, J Falloon, J Eddy, D A Katz, R P Friedland, S I Rapoport, P Brouwers, P A Pizzo.   

Abstract

The ventricular area at the level of the foramen of Monro was measured from axial x-ray computed tomography (CT) scans obtained prior to and 6 months after the initiation of continuous infusion of zidovudine (ZDV) in eight children with human immunodeficiency virus-induced encephalopathy. Evidence of moderate to severe central atrophy was present on initial CT scans (p less than 0.05). Ventricular area and ventricular brain area ratio (VBR) decreased after ZDV therapy in seven of eight children (mean decrease of 21.5 and 20%, respectively, p less than 0.05). The degree of decrease in VBR correlated with reductions in cerebrospinal fluid (CSF) protein concentration (r = 0.93, p less than 0.01), but not lymphocyte T4 or T8 counts. Intelligence quotients (IQs) improved in all seven children tested (mean improvement of 17.7%, p less than 0.01) and correlated significantly with reductions in CSF protein concentration (r = -0.85, p = 0.003). The magnitude of IQ changes was not significantly correlated with the magnitude of changes in ventricular area. We conclude that the cognitive improvement of HIV encephalopathy seen after 6 months of continuous infusion of ZDV is accompanied by reduction in brain atrophy and decreased CSF protein, suggesting an ameliorating effect of ZDV on the pathogenesis of AIDS encephalopathy in children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673712

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  6 in total

1.  Magnetic resonance imaging traits in siblings discordant for Alzheimer disease.

Authors:  Karen T Cuenco; Robert C Green; J Zhang; Kathryn Lunetta; Porat M Erlich; L Adrienne Cupples; Lindsay A Farrer; Charles DeCarli
Journal:  J Neuroimaging       Date:  2008-07       Impact factor: 2.486

2.  Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.

Authors:  Sarah Benki-Nugent; Christal Eshelman; Dalton Wamalwa; Agnes Langat; Ken Tapia; Helen Moraa Okinyi; Grace John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

Review 3.  Vertical human immunodeficiency virus-1 infection: involvement of the central nervous system and treatment.

Authors:  C Exhenry; D Nadal
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

4.  Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease.

Authors:  Sanneke Koekkoek; Laura Eggermont; Leo De Sonneville; Thidakat Jupimai; Saijai Wicharuk; Wichitea Apateerapong; Theshinee Chuenyam; Joep Lange; Ferdinand Wit; Chitsanu Pancharoen; Praphan Phanuphak; Jintanat Ananworanich
Journal:  J Neurol       Date:  2006-11-08       Impact factor: 4.849

Review 5.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

6.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation.

Authors:  Y Li; H Hui; C J Burgess; R W Price; P M Sharp; B H Hahn; G M Shaw
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.